New Enhanced OMIDRIAssure® Patient Access Programs

Learn more

Real-world evidence

OMIDRIA reduces postoperative cme rates

Incidence of post-op CME in patients without pre-op VMT was reduced by 65% when OMIDRIA + BromSite was administered vs Lotemax + Prolensa

Retrospective analysis was performed on 2218 cataract procedures at a single site.1

OMIDRIA reduces the incidence of CME without the use of steroid drops.1

VMT=vitreomacular traction.

Retrospective, 2-cohort study (N=2218)1

In a retrospective, 2-cohort study, the incidence of CME, breakthrough iritis, and pain were compared between patients who received OMIDRIA or topical loteprednol

All eyes in both groups received bromfenac ophthalmic solution 0.07% for 2 days prior to surgery and 10 weeks postoperatively.1

Continuous delivery of OMIDRIA for consistent therapeutic benefits

Consistent inhibition of COX1 and COX2 in the vitreous, iris/ciliary body and cornea at 0, 2, 6, 8 and 10 hours

Intracameral administration of diluted phenylephrine and ketorolac 1%/0.3% was found to achieve therapeutic levels of ketorolac during surgery in both the aqueous and vitreous humors.3

  • With OMIDRIA, ketorolac levels in intraocular structures inhibit COX-1 and COX-2 for at least 10 hours postoperatively, decreasing concentrations of prostaglandins to reduce pain due to surgical trauma3
  • Preoperative topical delivery of NSAIDs does not significantly inhibit postoperative levels of COX-1 or COX-23
  • Absorption of ketorolac into ocular tissues during surgery and the related inhibition of COX enzymes could potentially have a substantial effect on reducing inflammatory complications, such as CME or retinal thickening3,4


Canine Study3
This study was conducted in adherence to the ARVO Statement on the Use of Animals in Ophthalmic and Vision Research. Lens replacement surgery with phacoemulsification was performed in 20 female beagle dogs. A fixed combination of OMIDRIA was diluted 125-fold into the balanced salt solution and delivered intracamerally during the phacoemulsification procedure. Ketorolac concentration was determined by liquid chromatography/mass spectrometry.

REFERENCES: 1. Visco DM, Bedi R. Effect of intracameral phenylephrine 1.0%–ketorolac 0.3% on postoperative cystoid macular edema, iritis, pain, and photophobia after cataract surgery. J Cataract Refract Surg. 2020;46(6):867-872. 2. Florio V, Cowan L, Prusakiewicz JJ, Bentley E, Waterbury LD. Ocular tissue distribution of ketorolac after administration of OMS302 to dogs during IOL replacement. E-poster presented at: American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting; April 17-21, 2015; San Diego, CA. 3. Waterbury LD. Alternative drug delivery for patients undergoing cataract surgery as demonstrated in a canine model. J Ocul Pharmacol Ther. 2018;34:154-160. 4. Wittpenn JR, Silverstein S, Heier J, Kenyon KR, Hunkeler JD, Earl M; the Acular LS for Cystoid Macular Edema (ACME) Study Group. A randomized, masked comparison of topical ketorolac 0.4% plus steroid vs steroid alone in low-risk cataract surgery patients. Am J Ophthalmol. 2008;146(4):554-560.